Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference
SECAUCUS, N.J. , Sept. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that Sam Samad, Executive Vice President and...
Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Baird Global Healthcare Conference 2025 September 10, 2025 10:50 AM EDT Company Participants James Davis - Chairman, CEO & President Conference Call Parti...
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology b...
Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% fro...
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest beats quarterly profit estimates on strong demand for diagnostic tests
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2...
Quest Diagnostics to Host Investor Day on March 19, 2025
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and fina...
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6...
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from...
Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Related Companies